Bandingkan Harga & Kinerja Erajaya Swasembada Tbk. (ERAA) vs Organon Pharma Indonesia Tbk. (SCPI)
Kinerja harga (24 Jam Terakhir)
Statistik utama
Statistik utama
Perbedaan Erajaya Swasembada Tbk. dan Organon Pharma Indonesia Tbk.: Erajaya Swasembada Tbk. diperdagangkan di Rp595 (kapitalisasi pasar 9,41 T, volume 24 jam 91,64 jt), sedangkan Organon Pharma Indonesia Tbk. diperdagangkan di Rp29.000 (kapitalisasi pasar 104,4 M). Perbedaan utamanya: Erajaya Swasembada Tbk. jauh lebih besar — sekitar 90,1× kapitalisasi pasar Organon Pharma Indonesia Tbk.. Mana yang lebih baik tergantung tujuan investasimu.
| ERAA | SCPI | |
|---|---|---|
Kapitalisasi Pasar | 9,41 T | 104,4 M |
Volume | 91,64 jt | — |
Lot | 916,38 rb | — |
Perputaran | 53,7 M | — |
Harga Rata-rata | 585,95 | — |
Nilai Transaksi | 53,7 M | — |
Harga Ekuilibrium Indikatif | 595 | — |
Volume Ekuilibrium Indikatif | 32,64 rb | — |
Perbandingan imbal hasil
Imbal hasil berjalan pada periode standar
Perbandingan imbal hasil
Imbal hasil berjalan pada periode standar
Berita terkini
Berita terbaru kedua aset
Berita terkini
Berita terbaru kedua aset
Tentang Erajaya Swasembada Tbk.
PT Erajaya Swasembada Tbk (the Company) was established in Jakarta based on Notarial Deed No.7 of Myra Yuwono, S.H., dated October 8, 1996. Erajaya Group is the official distributor for 10 international mobile communication brands and an authorised partner for major mobile operators. Recently, the Group has launched its own mobile handset under the name of Venera. In 1996, PT Erajaya Swasembada, or Erajaya, the establishment of what we know today as the Erajaya Group, was incorporated.
Selengkapnya di halaman ERAA →Tentang Organon Pharma Indonesia Tbk.
PT Merck Sharp Dohme Pharma Tbk was established within the frame work of the Foreign Capital Investment Law No. 1 year 1967 as amended by Law No. 11 year 1970 based on Notarial Deed No. 17 dated 7 March 1972 of Djojo Muljadi, S.H. The company originally incorporated as PT. Essex Indonesia, as a joint venture between Schering Corporation, a worldwide, research-based pharmaceutical enterprise headquartered in the United States, and an Indonesian businessman.
Selengkapnya di halaman SCPI →
